Head-to-Head Comparison
OpenEvidence vs Epocrates: Which Is Better for Physicians?
OpenEvidence: AI Research Assistant for Evidence-Based Clinical Decisions Epocrates: Drug Reference, Interaction Checker & Clinical Decision Support
Updated
Direct Answer
Source: Clinical AI Report, 2026
Key takeaways
- OpenEvidence cites licensed content from partners including NEJM, JAMA and NCCN, while Epocrates offers no natural-language search, AI clinical reasoning or evidence synthesis.
- Epocrates covers drug monographs, a multi-drug interaction checker and pill identification for free; Epocrates Plus adds disease content and lab references for $179.99 a year (October 2026).
- OpenEvidence has no drug dosing tools or differential diagnosis generator, so dosing questions belong in a drug reference such as Epocrates.
- Epocrates is built mobile-first with 600+ medical calculators, but its desktop experience is secondary and EHR integration for individual users is limited.
Feature Comparison
| Feature | OpenEvidence | Epocrates |
|---|---|---|
| Rating | OpenEvidence: Good | Epocrates: Fair |
| Category | OpenEvidence: AI Medical Research Assistant | Epocrates: Drug Reference & Clinical Decision Support |
| Pricing | OpenEvidence: Free (Ad-Supported) | Epocrates: Free (Basic) / $179.99/year (Plus) |
| Founded | OpenEvidence: 2022 | Epocrates: 1998 |
| Headquarters | OpenEvidence: Miami, FL | Epocrates: San Mateo, CA |
| Evidence Citations | OpenEvidence: Yes | Epocrates: No |
| AI Differential Diagnosis | OpenEvidence: No | Epocrates: No |
| Drug Database | OpenEvidence: No | Epocrates: Yes |
| Drug Interaction Checker | OpenEvidence: No | Epocrates: Yes |
| Medical Calculators | OpenEvidence: Yes | Epocrates: Yes |
| Natural Language Search | OpenEvidence: Yes | Epocrates: No |
| Document & Image Upload | OpenEvidence: No | Epocrates: No |
| EHR Integration | OpenEvidence: Yes | Epocrates: No |
| Mobile App | OpenEvidence: Yes | Epocrates: Yes |
| Built-in Dialer | OpenEvidence: Yes | Epocrates: No |
| AI Clinical Scribe | OpenEvidence: No | Epocrates: No |
| CME Credits | OpenEvidence: No | Epocrates: No |
| Multi-Language | OpenEvidence: Yes | Epocrates: No |
Strengths & Limitations
OpenEvidence
Strengths
- +Useful for generalist clinical questions — fast, cited answers for everyday practice
- +Widely adopted clinical AI in the US (757K+ physicians)
- +Free for all verified physicians
- +Broadest content partnership network: NEJM, JAMA (all 11 specialty journals), NCCN, ACC, AAFP, ACEP, ADA, AAOS, 300+ journals
- +Native iOS and Android apps with Home Screen widgets
- +Quick Consult and Deep Consult modes for different clinical needs
- +Built-in dialer for calling patients, pharmacies, and colleagues
- +Well-funded with strong investor backing ($12B valuation, $100M annual revenue)
Limitations
- –No differential diagnosis generation or drug dosing tools
- –Ad-supported revenue model (pharmaceutical/healthcare advertising)
- –EHR integration is early-stage (Sutter Health/Epic announced February 2026)
- –Preprint by Jagarapu et al. (2025) reported 41% accuracy on complex subspecialty scenarios
- –Clinical depth narrower than platforms with drug databases and medical calculators
Epocrates
Strengths
- +Free tier with genuinely useful drug interaction checker and monographs
- +Fast, well-designed mobile app optimized for point-of-care use
- +Over 1 million active healthcare professional users
- +Includes a pill identification tool
- +Affordable Plus tier at $179.99/year compared to competitors
- +Long track record since 1998 with consistent reliability
Limitations
- –No AI-powered differential diagnosis or clinical reasoning
- –Disease content lacks depth compared to UpToDate or DynaMed
- –No natural-language query support or evidence synthesis
- –Limited EHR integration for individual users
- –Plus tier content updates can lag behind newer platforms
Key Statistics
OpenEvidence
Epocrates
Citable Summaries
OpenEvidence
OpenEvidence has an editorial score of 73/100 (3.7/5), calculated from Clinical AI Report's published criteria weights. It ranks #2 among 7 general clinical decision support tools under this rubric. The score is an editorial assessment, not an aggregate of user reviews or a clinical performance benchmark.
Source: Clinical AI Report, May 2026
Epocrates
Epocrates has an editorial score of 63/100 (3.2/5), calculated from Clinical AI Report's published criteria weights. It ranks #6 among 7 general clinical decision support tools under this rubric. The score is an editorial assessment, not an aggregate of user reviews or a clinical performance benchmark.
Source: Clinical AI Report, May 2026
Our Assessment
In our 2026 evaluation, OpenEvidence (ranked #2, 3.7 stars) outperforms Epocrates (ranked #6, 3.2 stars) in overall physician satisfaction and editorial scoring. OpenEvidence is best suited for a useful tool for physicians who need fast, cited answers to clinical questions grounded in peer-reviewed literature. Relevant for primary care, internal medicine, and emergency medicine. Free and backed by a broad content partnership network (NEJM, JAMA, NCCN, ACC, AAFP, ACEP). Meanwhile, Epocrates is a stronger choice for physicians and residents seeking a fast, reliable, mobile-first drug reference tool with a strong free tier — especially for interaction checks and dosing at the point of care. Both tools serve important but distinct roles in clinical care workflows, and physicians should choose based on their specific workflow requirements and institutional needs.